Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: A longitudinal analysis

Pharmacotherapy

Volumn 27, Issue 9 I, 2007, Pages 1237-1247

  Shalansky, Stephen ^a,b,e   Lynd, Larry ^b,c   Richardson, Kathryn ^c   Ingaszewski, Andrew ^d   Kerr, Charles ^d  

^a VANCOUVER COASTAL HEALTH   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^d ST PAUL S HOSPITAL   (Canada)

^e LIONS GATE HOSPITAL   (Canada)

Author keywords

Adverse events; Bleeding events; CAM; Complementary and alternative medicine; Dietary interactions; Drug interactions; INR; International normalized ratio; Risk factors; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ALPHA TOCOPHEROL; AMIODARONE; CELECOXIB; CEPHALOSPORIN DERIVATIVE; CLOPIDOGREL; DICLOFENAC; ETODOLAC; GLIBENCLAMIDE; GLUCOSAMINE; IBUPROFEN; INDOMETACIN; LEVOTHYROXINE; MEVINOLIN; NABUMETONE; OMEPRAZOLE; PARACETAMOL; PAROXETINE; PHENYLBUTAZONE; PROPAFENONE; QUINIDINE; QUININE; RANITIDINE; SERTRALINE; SULFONAMIDE; UBIDECARENONE; UNINDEXED DRUG; VITAMIN K GROUP; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CANADA; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG POTENCY; FEMALE; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GINGER; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT CARE; PEPPER; PRESCRIPTION; RISK ASSESSMENT; TREATMENT DURATION; WILLOW;

ACETAMINOPHEN; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CANADA; COENZYMES; COMPLEMENTARY THERAPIES; DIARRHEA; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; ETHANOL; FEMALE; GINGER; HEMORRHAGE; HERB-DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANTS, MEDICINAL; PROSPECTIVE STUDIES; RISK FACTORS; UBIQUINONE; VITAMINS; WARFARIN;

EID: 34548299671     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.9.1237     Document Type: Article

References (44)

1. Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S204-33. (Erratum in Chest 2005;127:415-16.)
2. Anonymous. Top 200 generic drugs by units in 2006. Drug topics 2007. Available from http://dtopics.adv100.com/drugtopics/data/articlestandard/ drugtopics/092007/407652/article.pdf. Accessed June 12, 2007.
3. Anonymous. Top 200 brand name drugs by units in 2006. Drug topics 2007. Available from http://dtopics.adv100.com/drugtopics/data/articlestandard/ drugtopics/092007/407649/article.pdf. Accessed June 12, 2007.
4. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S287-310.
5. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ 2002;325:828-31.
6. Wittkowsky AK, Devine EB. Frequency and causes of overanticoagulation and underanticoagulation in patients treated with warfarin. Pharmacotherapy 2004;24:1311-16.
7. Tindle HA, Davis RB, Phillips RS, Eisenberg DM. Trends in use of complementary and alternative medicine by U.S. adults: 1997-2002. Altern Ther Health Med 2005;11:42-9.
8. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
9. Pharand C, Ackman ML, Jackevicius CA, Paradiso-Hardy FL, Pearson GJ. Use of OTC and herbal products in patients with cardiovascular disease. Ann Pharmacother 2003;37:899-904.
10. Ramsay NA, Kenny MW, Davies G, Patel JP. Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 2005;130:777-80.
11. Wood MJ, Stewart RL, Merry H, Johnstone DE, Cox JL. Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 2003;145:806-12.
12. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998;158:2200-11.
13. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health-Syst Pharm 1999;56:125-38.
14. Fugh-Berman A. Herb-drug interactions. Lancet 2000;355:134-8.
15. Boullata JI, Nace AM. Safety issues with herbal medicine. Pharmacotherapy 2000;20:257-69.
16. Coxeter PD, McLachlan AJ, Duke CC, Roufogalis BD. Herb-drug interactions: an evidence-based approach. Curr Med Chem 2004;11:1513-25.
17. Shalansky S, Lynd L, Ignaszewski A, Kerr C, Vickars L, Abd- Elmessih E. The effect of complementary and alternative medicine usage patterns on warfarin-related adverse events [abstract]. Can J Cardiol 2003;19:164A.
18. Diggle P, Liang K, Zeger S. Analysis of longitudinal data. London: Oxford University Press, 1994.
19. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-51.
20. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med 2004;141:745-52.
21. Roberge RJ, Rao P, Miske GR, Riley TJ. Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine. Vet Hum Toxicol 2000;42:351-3.
22. Smith JK, Aljazairi A, Fuller SH. INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother 1999;33:301-4.
23. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-62.
24. Havrda DE, Mai T, Chonlahan J. Enhanced antithrombotic effect of warfarin associated with low-dose alcohol consumption. Pharmacotherapy 2005;25:303-7.
25. Gage BF, Fihn SD, White RH. Seasonal control of warfarin therapy [letter]. Am J Med 2001;111:332.
26. Salobir B, Sabovic M, Peternel P. Intensity of long-term treatment with warfarin is influenced by seasonal variations. Pathophysiol Haemost Thromb 2002;32:151-4.
27. Stys T, Stys A, Kelly P, Lawson W. Trends in use of herbal and nutritional supplements in cardiovascular patients. Clin Cardiol 2004;27:87-90.
28. Smith L, Ernst E, Ewings P, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. Br J Gen Pract 2004;54:439-41.
29. Zuckerman IH, Steinberger EK, Ryder PT, Haines S. Herbal product use among anticoagulation clinic patients. Am J Health-Syst Pharm 2002;59:379-80.
30. Wong RS, Cheng G, Chan TY. Use of herbal medicines by patients receiving warfarin. Drug Saf 2003;26:585-8.
31. Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health-Syst Pharm 2000;57:1221-7.
32. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996;77:545-6.
33. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double-blind, placebo-crossover trial. Thromb Haemost 2002;87:1075-6.
34. Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med 2004;71:651-6.
35. Dorso CR, Levin RI, Eldor A, Jaffe EA, Weksler BB. Chinese food and platelets. N Engl J Med 1980;303:756-7.
36. Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin-relevance for medicine and psychiatry. Med Hypotheses 1986;20:271-8.
37. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000;34:1478-82.
38. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005;59:425-32.
39. Corrigan JJ Jr, Marcus FI. Coagulopathy associated with vitamin E ingestion. JAMA 1974;230:1300-1.
40. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99. (Erratum in N Engl J Med 1999;341:548.)
41. Chang ZG, Kennedy DT, Holdford DA, Smatl RE. Pharmacists' knowledge and attitudes toward herbal medicine. Ann Pharmacother 2000;34:710-15.
42. Dolder C, Lacro J, Dolder N, Gregory P. Pharmacists' use of and attitudes and beliefs about alternative medications. Am J Health-Syst Pharm 2003;60:1352-7.
43. Corbin Winslow L, Shapiro H. Physicians want education about complementary and alternative medicine to enhance communication with their patients. Arch Intern Med 2002;162:1176-81.
44. Suchard JR, Suchard MA, Steinfeldt JL. Physician knowledge of herbal toxicities and adverse herb-drug interactions. Eur J Emerg Med 2004;11:193-7.